Current status of thiopurine analogues in the treatment in Crohn's disease

World Journal of Gastroenterology

Volumn 17, Issue 39, 2011, Pages 4372-4381

  Lakatos, Peter Laszlo ^a   Kiss, Lajos S ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Azathioprine; Biologicals; Crohn's disease; Immunosuppressives; Thiopurine methyltransferase

Indexed keywords

ADALIMUMAB; ALLOPURINOL; AZATHIOPRINE; CERTOLIZUMAB PEGOL; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO;

ABDOMINAL PAIN; ALLERGIC REACTION; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; FEVER; FLU LIKE SYNDROME; HUMAN; LIVER TOXICITY; LYMPHOMA; MALAISE; NAUSEA; PANCREATITIS; RASH; REVIEW; TREATMENT RESPONSE;

EID: 81755188303     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i39.4372     Document Type: Review

References (63)

1. Lakatos PL, Fischer S, Lakatos L, Gal I, Papp J. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take "toll"? World J Gastroenterol 2006; 12: 1829-1841
2. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol 2006; 12: 6102-6108
3. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus Jr EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 Suppl A: 5-36
4. Louis E, Collard A, Oger AF, Degroote E, El Yafi FAAN, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782
5. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250
6. Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-1113
7. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-656
8. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-954
9. Wolters FL, Russel MG, Stockbrügger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20: 483-496
10. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppres-sants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241
11. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm Bowel Dis 2009; 15: 375-382
12. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-297
13. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. Early Crohn disease: a proposed defnition for use in dis-ease-modifcation trials. Gut 2010; 59: 141-147
14. Lakatos PL, Kiss LS. Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol 2010; 16: 2591-2599
15. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercap-topurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302: 981-987
16. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678
17. Saibeni S, Virgilio T, D'Incà R, Spina L, Bortoli A, Paccag-nella M, Peli M, Sablich R, Meucci G, Colombo E, Benedetti G, Girelli CM, Casella G, Grasso G, de Franchis R, Vecchi M. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. Dig Liver Dis 2008; 40: 814-820
18. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathio-prine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-489
19. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
20. Punati J, Markowitz J, Lerer T, Hyams J, Kugathasan S, Griffths A, Otley A, Rosh J, Pfefferkorn M, Mack D, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Mezoff A, Leleiko N, Keljo D, Crandall W. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis 2008; 14: 949-954
21. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-678
22. Jaspers GJ, Verkade HJ, Escher JC, de Ridder L, Taminiau JA, Rings EH. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 2006; 12: 831-836
23. Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsig-mond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol 2009; 15: 3504-3510
24. Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsig-mond F, Pandur T, Erdelyi Z, Gemela O, Papp M, Papp J, Lakatos PL. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmok-ers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol 2010; 22: 872-879
25. Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-strictur-ing Crohn's disease. Am J Gastroenterol 2009; 104: 2754-2759
26. Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol 2009; 15: 4234-4239
27. Jharap B, Seinen ML, de Boer NK, van Ginkel JR, Linskens RK, Kneppelhout JC, Mulder CJ, van Bodegraven AA. Thio-purine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-1549
28. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercap-topurine. Clin Gastroenterol Hepatol 2007; 5: 209-214
29. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010: CD000545
30. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009: CD000067
31. Treton X, Bouhnik Y, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, Cosnes J, Lemann M. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7: 80-85
32. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667
33. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gas-troenterology 2010; 138: 463-468; quiz e10-11
34. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Infuence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608
35. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppres-sive therapy in suppressing the formation of antibodies to infiximab in Crohn's disease. Gut 2007; 56: 1226-1231
36. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. Clinical trial: benefts and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226
37. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfeld R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238
38. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutg-eerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infiximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868
39. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Long-term outcome of treatment with infiximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500
40. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldas-sano R. Induction and maintenance infiximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-873; quiz 1165-1166
41. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rut-geerts P. Infiximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
42. Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-1368
43. Domènech E, Mañosa M, Bernal I, Garcia-Planella E, Cabré E, Piñol M, Lorenzo-Zúñiga V, Boix J, Gassull MA. Impact of azathioprine on the prevention of postoperative Crohn' s disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm Bowel Dis 2008; 14:508-513
44. D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenter-ology 2008; 135: 1123-1129
45. Peyrin-Biroulet L, Deltenre P, Ardizzone S, D'Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Azathio-prine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-2096
46. Papay P, Reinisch W, Ho E, Gratzer C, Lissner D, Herkner H, Riss S, Dejaco C, Miehsler W, Vogelsang H, Novacek G. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol 2010; 105: 1158-1164
47. Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR. Aza-thioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-759
48. Yamamoto T, Umegae S, Matsumoto K. Impact of inflix-imab therapy after early endoscopic recurrence following ileocolonic resection of Crohn's disease: a prospective pilot study. Inflamm Bowel Dis 2009; 15: 1460-1466
49. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43: 329-339
50. Dubinsky MC. Azathioprine, 6-mercaptopurine in infam-matory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004; 2: 731-743
51. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F. Lym-phoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625
52. Weinshilboum RM, Sladek SL. Mercaptopurine pharma-cogenetics: monogenic inheritance of erythrocyte thiopu-rine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662
53. Krynetski EY, Evans WE. Genetic polymorphism of thiopu-rine S-methyltransferase: molecular mechanisms and clinical importance. Pharmacology 2000; 61: 136-146
54. Colombel JF, Ferrari N, Debuysere H, Marteau P, Gendre JP, Bonaz B, Soulé JC, Modigliani R, Touze Y, Catala P, Libersa C, Broly F. Genotypic analysis of thiopurine S-meth-yltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenter-ology 2000; 118: 1025-1030
55. Sandborn WJ. A review of immune modifer therapy for in-fammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-433
56. Lees CW, Maan AK, Hansoti B, Satsangi J, Arnott ID. Toler-ability and safety of mercaptopurine in azathioprine-intol-erant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27: 220-227
57. Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathio-prine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; 29: 654-661
58. Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, Duclos B, Seksik P, Mary JY, Colombel JF. Nodular regenerative hyperplasia in patients with infam-matory bowel disease treated with azathioprine. Gut 2007; 56: 1404-1409
59. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercapto-purine. Gut 2005; 54: 1121-1125
60. Dayharsh GA, Loftus EV, Sandborn WJ, Tremaine WJ, Zins-meister AR, Witzig TE, Macon WR, Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopu-rine. Gastroenterology 2002; 122: 72-77
61. Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F. Lym-phoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-1625
62. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T. cell lymphoma in inflammatory bowel disease. Gut 2008; 57: 1639-1641
63. Toruner M, Loftus EV, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with Inflamma-tory bowel disease. Gastroenterology 2008; 134: 929-936